South Korea · Delayed Price · Currency is KRW PanGen Biotech Statistics
Total Valuation
PanGen Biotech has a market cap or net worth of KRW 67.50 billion. The enterprise value is 55.46 billion.
| Market Cap | 67.50B |
| Enterprise Value | 55.46B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
PanGen Biotech has 13.51 million shares outstanding. The number of shares has increased by 8.54% in one year.
| Current Share Class | 13.51M |
| Shares Outstanding | 13.51M |
| Shares Change (YoY) | +8.54% |
| Shares Change (QoQ) | +19.05% |
| Owned by Insiders (%) | 4.06% |
| Owned by Institutions (%) | n/a |
| Float | 6.39M |
Valuation Ratios
The trailing PE ratio is 64.72.
| PE Ratio | 64.72 |
| Forward PE | n/a |
| PS Ratio | 4.76 |
| PB Ratio | 2.20 |
| P/TBV Ratio | 2.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 48.99 |
| EV / Sales | 3.91 |
| EV / EBITDA | 31.37 |
| EV / EBIT | 235.63 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.55, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.55 |
| Quick Ratio | 6.12 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | -0.00 |
| Interest Coverage | 1.88 |
Financial Efficiency
Return on equity (ROE) is 3.76% and return on invested capital (ROIC) is 1.25%.
| Return on Equity (ROE) | 3.76% |
| Return on Assets (ROA) | 0.42% |
| Return on Invested Capital (ROIC) | 1.25% |
| Return on Capital Employed (ROCE) | 0.76% |
| Weighted Average Cost of Capital (WACC) | 3.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.40 |
| Inventory Turnover | 1.29 |
Taxes
In the past 12 months, PanGen Biotech has paid 2.91 million in taxes.
| Income Tax | 2.91M |
| Effective Tax Rate | 0.26% |
Stock Price Statistics
The stock price has decreased by -18.26% in the last 52 weeks. The beta is -0.12, so PanGen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.12 |
| 52-Week Price Change | -18.26% |
| 50-Day Moving Average | 4,808.60 |
| 200-Day Moving Average | 5,302.93 |
| Relative Strength Index (RSI) | 53.42 |
| Average Volume (20 Days) | 7,549 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PanGen Biotech had revenue of KRW 14.18 billion and earned 1.13 billion in profits. Earnings per share was 77.18.
| Revenue | 14.18B |
| Gross Profit | 3.99B |
| Operating Income | 235.37M |
| Pretax Income | 1.14B |
| Net Income | 1.13B |
| EBITDA | 1.77B |
| EBIT | 235.37M |
| Earnings Per Share (EPS) | 77.18 |
Balance Sheet
The company has 12.05 billion in cash and 7.39 million in debt, with a net cash position of 12.04 billion or 891.20 per share.
| Cash & Cash Equivalents | 12.05B |
| Total Debt | 7.39M |
| Net Cash | 12.04B |
| Net Cash Per Share | 891.20 |
| Equity (Book Value) | 30.75B |
| Book Value Per Share | 1,914.07 |
| Working Capital | 21.31B |
Cash Flow
In the last 12 months, operating cash flow was -2.56 billion and capital expenditures -878.49 million, giving a free cash flow of -3.44 billion.
| Operating Cash Flow | -2.56B |
| Capital Expenditures | -878.49M |
| Depreciation & Amortization | 1.53B |
| Net Borrowing | -1.06B |
| Free Cash Flow | -3.44B |
| FCF Per Share | -254.51 |
Margins
Gross margin is 28.11%, with operating and profit margins of 1.66% and 7.99%.
| Gross Margin | 28.11% |
| Operating Margin | 1.66% |
| Pretax Margin | 8.01% |
| Profit Margin | 7.99% |
| EBITDA Margin | 12.47% |
| EBIT Margin | 1.66% |
| FCF Margin | n/a |
Dividends & Yields
PanGen Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.54% |
| Shareholder Yield | -8.54% |
| Earnings Yield | 1.68% |
| FCF Yield | -5.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PanGen Biotech has an Altman Z-Score of 19.94 and a Piotroski F-Score of 3.
| Altman Z-Score | 19.94 |
| Piotroski F-Score | 3 |